GlassScriptPhysician profile
Glenn Vallecillos
NPI 1902948615
$70,682.26
in general payments reported to CMS, 2019-2025
11 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.20 · 2020: $14.21 · 2021: $693 · 2022: $25K · 2023: $9,689 · 2024: $24K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $7,500 · Travel and Lodging: $2,552 · Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,000.00 |
| Consulting Fee | $7,500.00 |
| Travel and Lodging | $2,552.00 |
| Food and Beverage | $1,823.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $59,061.17 | 2021-2025 | Dysport |
| Solta Medical, A Division of Bausch Health US, LLC | $10,237.84 | 2023-2025 | Fraxel, Clear & Brilliant |
| Abbvie INC. | $316.34 | 2023-2024 | Natrelle Saline-Filled Breast Implants, Botox |
| Allergan, INC. | $279.85 | 2020-2022 | |
| Merz North America, INC. | $211.82 | 2019-2022 | |
| Kerecis Limited | $198.65 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Revance Therapeutics, INC. | $162.81 | 2024 | Daxxify, Daxi |
| Mentor Worldwide LLC | $102.70 | 2024 | |
| Davol INC. | $53.09 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $29.24 | 2024 | |
| Tela Bio, INC. | $28.75 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Vallecillos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.